Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions
Interventions
Paclitaxel
Carboplatin
+3 more
Locations
268
United States
St. Joseph'S Hospital & Medical Center
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona, United States
Arizona Oncology - HOPE Wilmot
Tucson, Arizona, United States
Moores Cancer Center at UC San Diego Health
La Jolla, California, United States
LAC + USC Medical Center
Los Angeles, California, United States
UCLA - School of Medicine
Los Angeles, California, United States
Start Date
March 8, 2017
Primary Completion Date
February 8, 2022
Completion Date
August 12, 2022
Last Updated
February 17, 2023
NCT06257264
NCT06964009
NCT06547840
NCT05080946
NCT07498829
NCT06503146
Lead Sponsor
Hoffmann-La Roche
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions